ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.
Developer of smart visual management platform and applications. The company specializes in developing digital twin visualization toolkits, including a 3D engine, development SDK, 3D application editor, 3D city editor, 3D campus editor, and 2D topology editor, providing users to build digital twin solutions along with effective visual management solutions to various fields. The company raised approximately CNY 180 million of Series B+ venture funding in a deal led by China Broadband Capital Partners and Chenshan Capital on April 26, 2020. Hundsun Technologies and Oriental Fortune Capital also participated in the round. This round of financing will be used for further researchmore
Shanghai Xisoft Technology Co., Ltd. specializes in the development of mobile applications and online solutions focused on hospital operation management. Founded in 2018 and headquartered in Shanghai, the company offers a range of products, including the Xisoft Hospital Operation Management System (HRP), which serves as an information-sharing platform for managing hospital resources. Additionally, the Xiaoxi Handheld HRP is a mobile application that consolidates various hospital functions, such as contact management, salary inquiries, project management, and conference coordination. The Xiyun Platform further enhances hospital management by providing data extraction and calculation services. With a growing presence through offices in multiple cities across China, XiSoft aims to improve the efficiency and effectiveness of hospital operations.
ForwardX Robotics, Inc. is a technology company specializing in artificial intelligence and robotics, with a focus on developing innovative solutions for logistics and manufacturing sectors. Founded in 2016 and headquartered in Beijing, China, the company also has offices in San Diego and Phoenix, United States. ForwardX is recognized for its mobile robotics vision-powered products, including a side-follow suitcase called Ovis, which integrates GPS and 3G technology for tracking. The company holds over 160 pending patents and employs a team of more than 180 professionals, including 120 engineers, many of whom are top experts in computer vision and robotics. ForwardX's offerings, including Autonomous Mobile Robots and Fleet Manager, are designed to improve operational efficiency and address challenges such as rising labor costs and productivity issues within the industry.
Star Charge focuses on developing and manufacturing the new energy vehicle charging equipment.
Developer of a web-based DevOps lifecycle tool in China. The company's software provides a Git-repository manager providing wiki, issue-tracking and continuous integration and deployment pipeline features to help clients throughout a software development lifecycle.
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.
XINGYUN GROUP is a comprehensive services platform for global commodities in China, devoting to providing global channel operation, distribution, and supply chain services to brands, retailers, and international trade practitioners.
Fujian Zongteng Network Co., Ltd. provides warehouse and logistics services for e-commerce sellers. The company also operates export auto parts and household products business. It also offers warehousing and distribution, small-package logistics, transportation services and supply chain finance, and value added services for cross-border e-commerce companies. Fujian Zongteng Network Co., Ltd. was founded in 2007 and is based in Shenzhen, China. It has additional offices in Guangzhou and Shanghai, China and Monroe, New Jersey.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.
CStone Pharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development and commercialization of innovative immuno-oncology and molecularly targeted drugs aimed at addressing unmet medical needs in cancer treatment. Founded in 2015, the company has a diverse product pipeline that includes late-stage clinical candidates such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, targeting programmed death receptor. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed for various types of cancer, including gastrointestinal stromal tumors and medullary thyroid cancer. CStone has established strategic partnerships and collaborations, including agreements with Numab Therapeutics AG and Bayer HealthCare LLC, to enhance its research and development efforts. The company aims to provide effective therapeutic options tailored to the needs of cancer patients both in China and globally.
Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.
Private Equity Round in 2018
Beijing Easyhome Home New Retail Chain Group Co., Ltd. is a prominent retail business based in China, specializing in home improvement and furniture. It operates 223 physical stores across 29 provinces, positioning itself as the second largest home furnishing and DIY chain in the country. In addition to its retail operations, Easyhome is involved in commercial property development and shopping mall decoration. The company also engages in e-commerce and owns various retail formats, including department stores, hypermarkets, and cheap supermarkets. Its diverse portfolio includes leasing and project development services, catering to a wide range of consumer needs in the home improvement sector.
Beijing Easyhome Home New Retail Chain Group Co., Ltd. is a prominent retail business based in China, specializing in home improvement and furniture. It operates 223 physical stores across 29 provinces, positioning itself as the second largest home furnishing and DIY chain in the country. In addition to its retail operations, Easyhome is involved in commercial property development and shopping mall decoration. The company also engages in e-commerce and owns various retail formats, including department stores, hypermarkets, and cheap supermarkets. Its diverse portfolio includes leasing and project development services, catering to a wide range of consumer needs in the home improvement sector.
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.
Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.
Womai Co., Ltd. owns and operates an online food retailing platform in China. The company offers imported food, fresh fruits and vegetables, grain and oil rice noodles, local specialties, snack food, brewed drinks, biscuit cakes, baby food, alcohol, and tea. It was founded in 2008 and is based in Beijing, China. Womai Co., Ltd. operates as a subsidiary COFCO Corporation. Womai Co., Ltd. operates as a subsidiary of COFCO Corporation
BGI Tech Solutions Co., Ltd., founded in 2012 and headquartered in Shenzhen, China, is a leading biotechnology company specializing in advanced life sciences technology. The company offers a wide range of services, including bioinformatics, genetic testing, and agricultural genomics research. BGI Tech operates lab facilities in Hong Kong, Wuhan, and Sacramento, and has a global service network that spans over 100 countries and regions. With collaborations involving more than 10,000 organizations and 30,000 partners, BGI Tech supports numerous research projects, including large-scale international genome initiatives. The company is committed to developing integrated omics platforms and aims to address various challenges in health, agriculture, energy, and environmental sectors, thereby contributing to scientific advancement and improving societal well-being.